Alió J L, Plaza-Puche A B, Cavas F, Yébana Rubio P, Sala E
Vissum Alicante, Departamento de Investigación, Desarrollo e Innovación, Alicante, España; División de Oftalmología, Departamento de Patología y Cirugía, Universidad Miguel Hernández, Alicante, España.
Vissum Alicante, Departamento de Investigación, Desarrollo e Innovación, Alicante, España.
Arch Soc Esp Oftalmol. 2017 Jan;92(1):4-11. doi: 10.1016/j.oftal.2016.05.009. Epub 2016 Jul 21.
To evaluate the efficacy and safety of an angle-supported foldable phakic intraocular lens (pIOL) for the correction of moderate to high myopia after 5 years follow-up.
Prospective and retrospective, observational, longitudinal, non-randomised consecutive series of cases conducted on a total of 100 eyes of 67 patients with moderate to high myopia implanted with an Acrysof Cachet pIOL (Alcon Laboratories Inc.) with the aim of minimising the refractive error. The ages ranged between 18 to 60years. Uncorrected distance visual acuity (UDVA), manifest refraction, corrected distance visual acuity (CDVA), endothelial cells density, pIOL position, intraocular pressure, and complications were recorded preoperatively and during the 5 year follow-up.
Five years after implantation, the mean manifest spherical equivalent refraction reduced significantly from -11.62±3.35 dioptres (D) to -0.33±0.85D. UDVA was 20/20 or better in 5 of 25 cases (20%), and 20/40 or better in 22 cases (88%). CDVA was 20/20 or better in 17 cases (68%), and 20/32 or better in 23 cases (92%) of eyes. The residual refractive error was within ±0.50D of emmetropia in 12 cases (48%), and within ±1.00D in 19 cases (76%). Mean endothelial cell loss at 5 years was 11.8% central, and 13.7% peripheral. Mean endothelium-pIOL distance was 2.11±0.18mm, and mean pIOL-crystalline distance was 0.88±0.20mm.
This angle supported pIOL provided a favourable refractive correction and predictability, as well as acceptable safety in patients with moderate to high myopia. Although endothelial cell density decreased over 5years, the results are within the range reported in previous studies with other pIOLs.
评估角支撑可折叠有晶状体眼人工晶状体（pIOL）矫正中高度近视5年后的有效性和安全性。
对67例中高度近视患者的100只眼进行前瞻性和回顾性、观察性、纵向、非随机连续病例系列研究，植入爱尔康公司的Acrysof Cachet pIOL，目的是尽量减少屈光不正。年龄在18至60岁之间。术前及5年随访期间记录未矫正远视力（UDVA）、显验光、矫正远视力（CDVA）、内皮细胞密度、pIOL位置、眼压及并发症。
植入后5年，平均显验光球镜等效度从-11.62±3.35屈光度（D）显著降低至-0.33±0.85D。25例中有5例（20%）的UDVA为20/20或更好，22例（88%）为20/40或更好。17例（68%）眼的CDVA为20/20或更好，23例（92%）为20/32或更好。12例（48%）的残余屈光不正处于正视眼±0.50D范围内，19例（76%）处于±1.00D范围内。5年时中央平均内皮细胞损失为11.8%，周边为13.7%。平均内皮与pIOL距离为2.11±0.18mm，平均pIOL与晶状体距离为0.88±0.20mm。
这种角支撑pIOL为中高度近视患者提供了良好的屈光矫正和可预测性，以及可接受的安全性。虽然5年内内皮细胞密度有所下降，但结果在先前其他pIOL研究报告的范围内。
